M
Manisha H. Shah
Researcher at Ohio State University
Publications - 184
Citations - 22496
Manisha H. Shah is an academic researcher from Ohio State University. The author has contributed to research in topics: Neuroendocrine tumors & Thyroid cancer. The author has an hindex of 55, co-authored 173 publications receiving 17444 citations. Previous affiliations of Manisha H. Shah include University of Cincinnati Academic Health Center & The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao,Manisha H. Shah,Tetsuhide Ito,Catherine Lombard Bohas,Edward M. Wolin,Eric Van Cutsem,Timothy J. Hobday,Takuji Okusaka,Jaume Capdevila,Elisabeth G.E. de Vries,Paola Tomassetti,Marianne Pavel,Sakina Hoosen,Tomas Haas,Jeremie Lincy,David Lebwohl,Kjell Öberg +16 more
TL;DR: Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events.
Journal ArticleDOI
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri,Allan T. van Oosterom,Christopher R. Garrett,Martin E. Blackstein,Manisha H. Shah,Jaap Verweij,Grant A. McArthur,Ian Judson,Michael Heinrich,Jeffrey A. Morgan,Jayesh Desai,Christopher D.M. Fletcher,Suzanne George,Carlo L. Bello,Xin Huang,Charles M. Baum,Paolo G. Casali +16 more
TL;DR: A randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumour, noting significant clinical benefit, including disease control and superior survival.
Journal ArticleDOI
Revised American thyroid association guidelines for the management of medullary thyroid carcinoma
Samuel A. Wells,Sylvia L. Asa,Henning Dralle,Rossella Elisei,Douglas B. Evans,Robert F. Gagel,Nancy Y. Lee,Andreas Machens,Jeffrey F. Moley,Furio Pacini,Friedhelm Raue,Karin Frank-Raue,Bruce G. Robinson,M. Sara Rosenthal,Massimo Santoro,Martin Schlumberger,Manisha H. Shah,Steven G. Waguespack +17 more
TL;DR: The revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic medullary thyroid carcinoma (MTC) and hereditary MTC and developed 67 evidence-based recommendations to assist clinicians in the care of Patients with MTC.
Journal ArticleDOI
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurélien Marabelle,Dung T. Le,Paolo A. Ascierto,Anna Maria Di Giacomo,Ana De Jesus-Acosta,Jean Pierre Delord,Ravit Geva,Maya Gottfried,Nicolas Penel,Aaron R. Hansen,Sarina Anne Piha-Paul,Toshihiko Doi,Bo Gao,Hyun Cheol Chung,Jose A. Lopez-Martin,Yung-Jue Bang,Ronnie Shapira Frommer,Manisha H. Shah,Razi Ghori,Andrew K. Joe,Scott K. Pruitt,Luis A. Diaz +21 more
TL;DR: The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
Journal ArticleDOI
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger,Makoto Tahara,Lori J. Wirth,Bruce G. Robinson,Marcia S. Brose,Rossella Elisei,Mouhammed Amir Habra,Kate Newbold,Manisha H. Shah,Ana O. Hoff,Andrew G. Gianoukakis,Naomi Kiyota,Matthew H. Taylor,Sung Bae Kim,Monika K. Krzyzanowska,Corina E. Dutcus,B.D.L. Heras,J. Zhu,Steven I. Sherman +18 more
TL;DR: Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer.